NCT03804372 2025-02-27
CLL1818
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Terminated
Clinical Trials
9 trialsNCT04305444 2025-01-08
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Phase 2 Terminated
NCT02518750 2019-04-03
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01446900 2018-01-31
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
European Institute of Oncology
Phase 2 Terminated
NCT02227108 2017-04-06
Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma
MedImmune LLC
Phase 2 Terminated
NCT00751296 2016-06-16
Rev-CLL
University Health Network, Toronto
Phase 2 Terminated
NCT01119794 2015-08-26
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
Brown University
Phase 2 Terminated
NCT01127542 2011-12-05
RESPeCT
The Christie NHS Foundation Trust
Phase 2 Terminated
NCT00083473 2005-08-30
A Pilot Study of Pivanex in Patients With Chronic Lymphocytic Leukemia
Titan Pharmaceuticals
Phase 2 Terminated